Company: Chelsea Therapeutics International, Ltd.
Status: Acquired by Lundbeck (2014)
Headquarters: Charlotte, North Carolina, USA (previously)
Founded: 2004
Acquired by: H. Lundbeck A/S (June 2014, ~$658M deal)
Chelsea Therapeutics International was a biopharmaceutical company focused on the development and commercialization of products for the treatment of neurogenic orthostatic hypotension (nOH) and other disorders affecting the autonomic nervous system. The company's flagship product, Northera (droxidopa) for neurogenic orthostatic hypotension, received U.S. Food and Drug Administration (FDA) approval in 2014 for the treatment of symptomatic nOH, making it the first FDA-approved therapy for this indication[1].
Chelsea Therapeutics was acquired by H. Lundbeck A/S in June 2014 for approximately $658 million, adding a critical product to Lundbeck's neuroscience portfolio while expanding into autonomic medicine[2].
Mechanism of Action:
Droxidopa is a synthetic amino acid that serves as a prodrug of norepinephrine. Upon oral administration, droxidopa is converted to norepinephrine by the enzyme aromatic L-amino acid decarboxylase (AADC). This conversion occurs both in the periphery and in the CNS, allowing droxidopa to restore deficient norepinephrine levels in patients with autonomic failure[3].
Pharmacology:
Clinical Development:
The development program for droxidopa included multiple Phase 3 clinical trials demonstrating:
Clinical Trials:
| Trial | Phase | Population | Primary Endpoint | Result |
|---|---|---|---|---|
| NOH301 | Phase 3 | nOH (PD, PAF, diabetic neuropathy) | OHQ change from baseline | Positive |
| NOH302 | Phase 3 | nOH refractory to midodrine | OHQ, BP maintenance | Positive |
| NOH306 | Extension | Long-term safety | Safety/tolerability | Ongoing post-approval |
Patients with Parkinson's disease frequently develop neurogenic orthostatic hypotension due to:
Droxidopa addresses the underlying norepinephrine deficiency, making it particularly valuable for PD patients with autonomic failure.
| Attribute | Details |
|---|---|
| Brand Name | Northera |
| Generic Name | Droxidopa |
| Formulation | Oral capsules (100 mg, 200 mg, 300 mg) |
| Indication | Symptomatic neurogenic orthostatic hypotension |
| Approved Populations | Parkinson's disease, Multiple System Atrophy, Pure Autonomic Failure, Diabetic neuropathy |
| Dosing | 100-600 mg TID (three times daily) |
| FDA Approval Date | August 2014 |
| Schedule | Not scheduled (not a controlled substance) |
| Manufacturer | Lundbeck (post-acquisition) |
Efficacy in PD-Specific Studies:
Clinical trials specifically enriched for PD patients showed:
Safety Profile:
In June 2014, Lundbeck acquired Chelsea Therapeutics for approximately $658 million, representing a 72% premium over Chelsea's closing stock price at the time.
Strategic Rationale for Lundbeck:
Post-Acquisition:
Northera's approval represented a significant advance in the treatment of orthostatic hypotension in PD:
The availability of droxidopa also enabled combination therapy approaches:
FDA Approves Northera (droxidopa) for Neurogenic Orthostatic Hypotension. 2014. ↩︎
Chelsea Therapeutics Northera Approval Announcement. 2014. ↩︎
Gibbons CH, et al. Orthostatic hypotension in neurodegenerative disease. Clinical Autonomic Research. 2019. ↩︎